This article is more than 5 years old. Information may no longer be current.
Ipilimumab appeared effective for pretreated, metastatic mucosal melanoma
Click Here to Manage Email Alerts
Ipilimumab may be a viable therapeutic option for pretreated patients with metastatic mucosal melanoma, according to study results.
The analysis included 855 patients aged 16 years or older with stage III or IV melanoma who had either failed or could not tolerate prior treatments. Of them, 71 (8%) had metastatic mucosal melanoma. The remainder of the cohort had skin or ocular melanoma.
All patients received ipilimumab (Yervoy, Bristol-Myers Squibb) 3 mg/kg every 3 weeks for four doses. Patients who demonstrated an objective response or achieved stable disease were eligible to undergo retreatment upon disease progression.
Researchers used immune-related response criteria to conduct tumor assessments at baseline and at week 12.
Median follow-up was 21.8 months.
Among patients with mucosal melanoma, researchers reported a 12% response rate and 36% immune-related disease control rate. Median PFS was 4.3 months and median OS was 6.4 months.
Thirty-four percent of patients experienced treatment-related adverse events, and 9% reported grade 3 or grade 4 adverse events. The adverse events typically were manageable, researchers said.
Click Here to Manage Email Alerts